Legacy Wealth Asset Management LLC Has $2.55 Million Stock Position in Takeda Pharmaceutical Co. $TAK

Key Points

• Legacy Wealth Asset Management LLC reduced its stake in Takeda Pharmaceutical Co. by 11.2%, now holding 164,785 shares worth approximately $2.55 million.
• Institutional investors and hedge funds collectively own 9.17% of Takeda Pharmaceutical's stock, indicating significant institutional interest.
• Takeda's recent earnings beat expectations, reporting $0.52 earnings per share, surpassing analyst forecasts, although revenues fell short of estimates.

Legacy Wealth Asset Management LLC lowered its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 11.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 164,785 shares of the company's stock after selling 20,687 shares during the quarter. Takeda Pharmaceutical makes up approximately 0.6% of Legacy Wealth Asset Management LLC's holdings, making the stock its 24th biggest holding. Legacy Wealth Asset Management LLC's holdings in Takeda Pharmaceutical were worth $2,548,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TAK. Farther Finance Advisors LLC boosted its stake in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at about $125,000. Hexagon Capital Partners LLC boosted its stake in shares of Takeda Pharmaceutical by 52.9% in the 1st quarter. Hexagon Capital Partners LLC now owns 8,698 shares of the company's stock valued at $129,000 after purchasing an additional 3,008 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at about $156,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Takeda Pharmaceutical in a research note on Tuesday, October 14th. Zacks Research lowered shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold".

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $14.07 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.69. The company has a market capitalization of $44.75 billion, a PE ratio of 46.88 and a beta of 0.21. The firm's 50 day moving average is $14.81 and its 200-day moving average is $14.75.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.